Enanta Pharmaceuticals 在欧洲肝脏研究协会 (EASL) 国际肝脏大会™

StephenW

Enanta Pharmaceuticals 在欧洲肝脏研究协会 (EASL) 国际肝脏大会™ 2022 上宣布数据展示
2022 年 6 月 8 日

马萨诸塞州沃特敦--(美国商业资讯)--六月。 2022 年 8 月 8 日——Enanta Pharmaceuticals, Inc.（纳斯达克股票代码：ENTA）是一家致力于为病毒感染和肝病研发小分子药物的临床阶段生物技术公司，今天宣布来自 Enanta 乙型肝炎病毒内部开发项目组合的数据（ HBV) 及其针对非酒精性脂肪性肝炎 (NASH) 的许可外授权项目组合已被接受在 2022 年 6 月 22 日至 26 日在伦敦举行的 2022 年欧洲肝脏研究协会 (EASL) 国际肝脏大会上进行海报展示， 英国。

公司内部开发组合提供的临床数据将包括海报展示，重点介绍 Enanta 的 HBV 核心抑制剂 EDP-514 1b 期研究中病毒血症和 nuc 抑制 HBV 患者的发现。

作为其授权项目组合的一部分，Enanta 将展示最新的临床前数据海报，显示 HSD17B13 酶的新型抑制剂提供的肝保护作用。该公司还将展示其 EDP-297 的 1 期研究的临床结果，EDP-297 是一种新型、高效的法尼醇 X 受体激动剂，旨在治疗非酒精性脂肪性肝炎。

内部发展计划

2022 年 6 月 25 日，英国夏令时 09:00 – 18:00
SAT390：“EDP-514，一种新型泛基因型 II 类乙型肝炎病毒核心抑制剂：Nuc 抑制慢性乙型肝炎患者 28 天 1b 期研究的最终结果”
会议：乙型/丁型病毒性肝炎：治疗
主持人：Jordan Feld 博士

SAT393：“EDP-514，一种有效的泛基因型 II 类乙型肝炎病毒核心抑制剂在病毒血症、慢性乙型肝炎患者的 1b 期研究中显示出显着的 HBV DNA 和 HBV RNA 减少”
会议：乙型/丁型病毒性肝炎：治疗
主讲人：袁文峰博士

外授权计划

2022 年 6 月 25 日，英国夏令时 09:00 – 18:00
SAT109：“EDP-297：一种新型、高效、法尼醇 X 受体激动剂。健康成人第一阶段研究的结果”
会议：NAFLD：治疗
主讲人：阿拉艾哈迈德博士

SAT177：“HSD17B13 的药理学抑制作用在小鼠肝损伤模型中具有保肝作用”
会议：分子和细胞生物学
主讲人：Manuel Roqueta-Rivera 博士

2022 年国际肝病大会的完整科学计划以及摘要可在 https://easl.eu/event/international-liver-congress-2022/ 上找到。更多详细信息将在进行这些演示时提供。

关于 Enanta 制药公司。
Enanta 正在利用其强大的化学驱动方法和药物发现能力，成为发现和开发用于治疗病毒感染和肝病的小分子药物的领导者。 Enanta 的研发项目包括目前正在针对以下疾病目标开发的临床候选药物：呼吸道合胞病毒 (RSV)、SARS-CoV-2 (COVID-19) 和乙型肝炎病毒 (HBV)。 Enanta 还在人类偏肺病毒 (hMPV) 方面进行研究。

Enanta 的研发活动由其与 AbbVie 合作开发的丙型肝炎病毒 (HCV) 产品的特许权使用费提供资金。 Glecaprevir 是 Enanta 发现的一种蛋白酶抑制剂，是治疗慢性 HCV 感染的主要治疗方案之一，由 AbbVie 在许多国家以商品名 MAVYRET®（美国）和 MAVIRET®（ex-U.S.）（glecaprevir/匹伦他韦）。请访问 www.enanta.com 了解更多信息。

StephenW

Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
Jun 08, 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Jun. 8, 2022-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s internal development program portfolio for hepatitis B virus (HBV) and its out-licensing program portfolio for non-alcoholic steatohepatitis (NASH) have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 being held June 22 – 26, 2022 in London, United Kingdom.

Clinical data presented from the company’s internal development portfolio will include poster presentations highlighting findings from both viremic and nuc-suppressed HBV patients from Phase 1b studies of EDP-514, Enanta’s HBV core inhibitor.

As part of its out-licensing program portfolio, Enanta will present a late-breaker poster of preclinical data showing hepatoprotection provided by a novel inhibitor of the HSD17B13 enzyme. The company will also present clinical results from its Phase 1 study of EDP-297, a novel, highly potent Farnesoid X receptor agonist designed for the treatment of non-alcoholic steatohepatitis.

Internal Development Programs

June 25, 2022, 09:00 – 18:00 BST
SAT390: “EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a 28-Day Phase 1b Study in Nuc-Suppressed Chronic Hepatitis B Patients”
Session: Viral Hepatitis B/D: therapy
Presenter: Dr. Jordan Feld

SAT393: “EDP-514, a Potent Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Patients”
Session: Viral Hepatitis B/D: therapy
Presenter: Dr. Man-Fung Yuen

Out-Licensing Programs

June 25, 2022, 09:00 – 18:00 BST
SAT109: “EDP-297: A Novel, Highly Potent, Farnesoid X Receptor Agonist. Results of a Phase 1 Study in Healthy Adults”
Session: NAFLD: Therapy
Presenter: Dr. Alaa Ahmad

SAT177: “Pharmacologic Inhibition of HSD17B13 is Hepatoprotective in Mouse Models of Liver Injury”
Session: Molecular and Cell Biology
Presenter: Dr. Manuel Roqueta-Rivera

The full scientific program for The International Liver Congress 2022, as well as the abstracts, can be found at https://easl.eu/event/international-liver-congress-2022/. Further details will be available at the time of these presentations.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.